Both, RT-qPCR and Western blot analyses revealed that the three KMT2A-rearranged cell lines MV4-11 (KMT2A::AFF1), MM6 (KMT2A::MLLT3) and MOLM-13 (KMT2A::MLLT3) and the CB-derived cell line AF93 (KMT2A::MLLT3), recapitulate the low expression levels of SMAD1 observed in AML patients with KMT2A rearrangement. This evidence concerns the gene SMAD1 and acute myeloid leukemia.